fda warning letter compounding semaglutide october 2025 Last month, the issued 25 letters to telehealth companies over what it called false or misleading claims about compounded GLP-1 medications Compounded Semaglutide & Tirzepatide 2025:

They can monitor any potential side effects and make adjustments as necessary to ensure that the medication is both safe and effective for you

Semaglutide has the most extensive cardiovascular outcome data, with the SUSTAIN and SELECT trials demonstrating significant reductions in major adverse cardiovascular events

this is, of course, important since it demonstrates that GLP-1-based therapy does not impair this important counter-regulatory mechanism

Tesamorelin is primarily used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy, while IGF-1 LR3 is used to understand the biology behind the IGF-1 system